Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - valsartan; hydrochlorothiazide - film-coated tablet - 320 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - valsartan; hydrochlorothiazide - film-coated tablet - 320 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - valsartan; hydrochlorothiazide - film-coated tablet - 80 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - valsartan; hydrochlorothiazide - film-coated tablet - 160 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - valsartan; hydrochlorothiazide - film-coated tablet - 160 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - valsartan; hydrochlorothiazide - tablet - 80mg ; 12.5mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - valsartan; hydrochlorothiazide - tablet - 160mg ; 12.5mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - valsartan; hydrochlorothiazide - tablet - 160mg ; 25mg

Kanada - Inggeris - Health Canada

baxter corporation - sealer protein (human); aprotinin (synthetic); thrombin (human); calcium chloride - solution - 125mg; 3000kiu; 4unit; 40mcmol - sealer protein (human) 125mg; aprotinin (synthetic) 3000kiu; thrombin (human) 4unit; calcium chloride 40mcmol - hemostatics

Israel - Inggeris - Ministry of Health

merck sharp & dohme israel ltd - posaconazole - suspension - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses